24-02-2023 (analyst meet notes)
-
3 brands in top-100 of IPM and 5 in top-200. Targocid and Frisium are also leading in their categories. 70% sales from top 7 brands
-
Manufacturing facility in Goa along with 16 CMO, distributors: 3’000, pharmacies: 100’000
-
Like to like sales declined by 2% in Q4CY22 due to challenges in Targocid (faced supply chain issues)
-
Lantus: Draft notification will lead to 25% price erosion on the 3 SKUs. However, this price cut will be taken by the manufacturing arm (hence the parent) and the marketing arm (listed co) will not see any drop in margins
-
Lantus didn’t grow in CY22 because organization’s focus was on promoting Toujeo. Insulin glargine franchise (lantus + Toujeo) grew by 2%
-
NLEM portfolio: 15-16% which will go to 40% once Lantus comes under price control
-
Cardace and Frisium: Will see price reduction of ~14%
-
Clexane benefitted from covid demand and has shown sharp decline in CY22 (already under NLEM)
-
Growth drivers: Diabetes and consumer healthcare. Have reduced business units to 3 from 8 earlier. Transferred 200 MRs to the Diabetes division
-
Had 6.5 lakh prescription patients in 2020 which moved above 7 lakhs in 2021
-
D3 vitamin market size is 800 cr., growing at 3%. Sanofi’s market share is 5%
Disclosure: Not invested
| Subscribe To Our Free Newsletter |
